In addition, studies have demonstrated the modulation effects of mTORC1/2 on various human cells such as CD4, CD8, Treg, TAMs, cancer-associated fibroblasts (CAF), endothelial cells, and myeloid-derived suppressor cells (MDSCs) [10,11]. This evidence concerns the gene CD8A and cancer.